CompletedN/Aketamine

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

Sponsored by Massachusetts General Hospital

NCT ID
NCT01667926
Target Enrollment
37 participants
Start Date
2013-01
Est. Completion
2015-11

About This Study

Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. The results of the study could lead to development of new strategies for treating depression.

Conditions Studied

Major Depressive Disorder

Interventions

  • Ketamine
  • Placebo

Eligibility

Age:18 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Outpatient with sever treatment resistant depression
* Currently depressed
* Currently under regular psychiatric care
* On an aggressive antidepressant regimen, stable for 4 weeks.

Exclusion Criteria:

* No history of other major psychiatric illness, including bipolar
* No history of psychosis
* No history of drug abuse
* No major medical illness or unstable medical problem

Study Locations (1)

Depression Clinical and Reseach Program - MGH
Boston, Massachusetts, United States

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder | Huxley